HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy. Lapatinib is used in combination with other medication Capecitabine or Letrozole, which together, inhibit the growth of cancer cells in patients. Hetero has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in the country. The tablets, under the brand name 'Hertab', have been launched in the strength of 250 mg, the product is marketed and distributed by Hetero Healthcare Ltd and has been made available in two stock keeping units (SKUs). The tablets are used in combination with Capecitabine or Letrozole, which together inhibit the growth of cancer cells in patient.
Used to treat breast cancer.
* To be consumed as directed by physician.